ImmunoLogik GmbH

ImmunoLogik GmbH is located in Berlin, Germany on Am Borsigturm 100. ImmunoLogik GmbH is rated 3 out of 5 in the category company in Germany. THE CHALLENGE Worldwide more than 36 million people live with an HIV infection and thus with the expectation to develop AIDS sooner or later. Despite the available combined antiretroviral therapy, AIDS is far from being defeated. With an array of drugs, the therapy targets viral components and suppresses the replication of the virus and therewith in most cases the outbreak of the fatal AIDS disease. Due to the high mutation rate of the virus, new variations increasingly resistant against the existing drugs arise constantly. Additionally, many drugs cause severe side effects and cannot be permanently taken by a large number of patients. Therefore, despite the modern combined antiretroviral therapy annually around 22 000 HIV-infected alone in Western and Central Europe as well as USA die from the consequences of AIDS. OUR SOLUTION APPROACH The ImmunoLogik GmbH develops an innovative lead candidate for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.